Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
NCT01245816 · Cancer Prevention Pharmaceuticals, Inc. · PHASE3 · withdrawn · last registry update 2015-04-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Cancer Prevention Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ODC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-02-04Results posted on the registry: National Cancer Institute (NCI), Celecoxib + eflornithine (NCT00033371)
- 2015-01-22Results posted on the registry: National Cancer Institute (NCI), eflornithine + sulindac (NCT00118365)
- 2014-07-30Also stopped (withdrawn): Cancer Prevention Pharmaceuticals, Inc., difluoromethylornithine + Sulindac (NCT01636128)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision